Skip to main content
. 2014 Aug 7;21(10):3261–3267. doi: 10.1245/s10434-014-3908-y

Table 4.

Neoadjuvant treatment received by IHC/FISH conventionally classified subtypes

IHC/FISH Total
Luminal (HR+/HER2−) HER2+ Triple negative
NCT 183 6 91 280
NCT/trastuzumab 5a 117 1b 123
NCT/NET 3 0 0 3
NET 20 0 0 20
Total 211 123 92 426

a2 IHC/FISH equivocal patients, 1 BluePrint HER2, and 2 with a positive mRNA HER2 read out

b1 IHC/FISH equivocal patient